Bio Rad实验室-A 2024年度报告

We advance science and save lives, together. FINANCIALHIGHLIGHTS Looking back over the lastseveral years and all thechanges we have seen, bothinternally and externally, Iam reminded how importantresilience is to an organization. We entered the year anticipating a gradualimprovement, especially in biopharma, butthe pace of market recovery was slower thanexpected. While this created headwinds for ourLife Science segment, we returned to a morenormalized growth rate in our Clinical Diagnosticsbusiness. Even with the slower market recovery,our broad-based, multi-year transformationhelped us effectively navigate the changingconditions around us. In fact, looking back to the beginning of Bio-Radand thinking how we have continuously adaptedto changing markets, new technology, andnew ways to operate over the last 70 plusyears, resilience and adaptability have playeda big part in our success. At the same time,our commitment to quality and innovation,and a collective mindset of staying one stepahead, have enabled us to bring new anduseful products to our customers. For the full-year 2024, we reported sales of$2.6 billion compared to $2.7 billion in 2023. Ona currency-neutral basis, 2024 sales decreased3.6% year-over-year, driven by lower Life Sciencesales, and offset by stronger demand for ourClinical Diagnostics products. Compared to 2023, we saw a 30-basis pointimprovement in our gross margin. The grossmargin expansion was possible because ofinitiatives including the consolidation of severalEuropean manufacturing sites into our Singaporemanufacturing hub and the opening of a newdistribution center in Singapore. Collectively,these projects simplify our logistics networkand inventory management to better serveour customers in the Asia Pacific region.Both initiatives will also help us improveproduct margins going forward. And aswe implement these and other operationalimprovements, we continue to carefullymanage our operating expenses. 2024 was a year of change for Bio-Rad withthe addition of several new senior leaders. Theseasoned executives we have appointed tolead our operations, finance, supply chain, legal,Life Science, and Clinical Diagnostics segments,collectively bring decades of experience andfresh ideas to the organization. Together, we arededicated to enhancing customer satisfaction,operational excellence, and driving efficiencywhile fostering a culture of innovation andcontinuous improvement. On the product front, in 2024 we introducedtwo new Life Science research platforms— the ChemiDoc™Go Imaging System foranalyzing gels and western blots, and theddSEQ™Single-Cell Kit, a cost-effectivesample prep solution for researchers to easilyconduct single-cell gene expression andregulation analyses. In Life Science, we acquired Saber Bio, adevelopment-stage platform using our coredroplet technology for high-throughput discoveryof novel antibodies and T-cell receptors, whichplay a critical role in helping researchers identifypotential therapeutic drug candidates. We also expanded our library of assays foruse with Droplet Digital™PCR to advance earlydiagnosis and monitoring of various cancers,cell and gene therapy manufacturing, and foodsafety monitoring. In addition, we made investments andformed partnerships to drive thepenetration of our Droplet DigitalPCR platform into life scienceresearch and advanced clinical OFFICERS Clockwise from top center: Norman SchwartzChairman of the Board,Chief Executive Officer Jonathan P. DiVincenzoPresident,Chief Operating Officer Roop K. LakkarajuExecutive Vice President,Chief Financial Officer investing in supporting their growth whilebuilding positions in new molecular diagnosticapplications. In Life Science, we will continue tofocus on the biopharma sector, especially withour digital PCR and process chromatographyproducts, and new product development aroundcell biology. diagnostics. We partnered with the AlleghenyHealth Network of hospitals to generate clinicalevidence across various cancer types usingBio-Rad’s Droplet Digital PCR technologyfor minimal residual disease monitoring ofsolid tumor cancer patients after treatment.We made an investment in Oncocyte tosupport the commercialization of transplantmonitoring assays deploying Bio-Rad’s QX600™Droplet Digital PCR System, offering laboratorycustomers a highly sensitive alternative tocentralized sequencing test providers. Wealso invested in Geneoscopy to support thelaunch of their FDA-approved, non-invasivecolorectal cancer screening test utilizing ourdigital PCR platform. The operational improvements made over thelast several years put us in a position to continueto expand our margin profile. As the markets getback on a solid growth trajectory, this will furthersupport our margin expansion. We have an incredibly talented team, several newproducts in development, and we enter 2025with renewed focus on our mission to collaboratewith our customers in advancing science andimproving healthcare outcomes to save live